News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
748,642 Results
Type
Article (45847)
Company Profile (472)
Press Release (702307)
Multimedia
Podcasts (135)
Webinars (23)
Section
Business (210283)
Career Advice (2144)
Deals (36284)
Drug Delivery (131)
Drug Development (84479)
Employer Resources (175)
FDA (16852)
Job Trends (15304)
News (356237)
Policy (33758)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2725)
Accelerated approval (45)
Adcomms (29)
Allergies (166)
Alliances (51346)
ALS (202)
Alzheimer's disease (1807)
Antibody-drug conjugate (ADC) (392)
Approvals (17137)
Artificial intelligence (631)
Autoimmune disease (233)
Automation (50)
Bankruptcy (375)
Best Places to Work (11915)
BIOSECURE Act (21)
Biosimilars (207)
Biotechnology (332)
Bladder cancer (182)
Brain cancer (68)
Breast cancer (701)
Cancer (5470)
Cardiovascular disease (466)
Career advice (1811)
Career pathing (41)
CAR-T (313)
CDC (58)
Celiac Disease (2)
Cell therapy (844)
Cervical cancer (41)
Clinical research (72455)
Collaboration (2002)
Company closure (4)
Compensation (1295)
Complete response letters (80)
COVID-19 (2831)
CRISPR (107)
C-suite (1023)
Cystic fibrosis (157)
Data (7169)
Decentralized trials (3)
Denatured (44)
Depression (167)
Dermatology (59)
Diabetes (560)
Diagnostics (6932)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (317)
Drug pricing (207)
Drug shortages (30)
Duchenne muscular dystrophy (284)
Earnings (92578)
Editorial (66)
Employer branding (22)
Employer resources (154)
Events (122908)
Executive appointments (1067)
FDA (20325)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1685)
Gene editing (230)
Generative AI (53)
Gene therapy (714)
GLP-1 (1079)
Government (4881)
Grass and pollen (6)
Guidances (397)
Healthcare (19499)
HIV (75)
Huntington's disease (54)
IgA nephropathy (95)
Immunology and inflammation (305)
Immuno-oncology (87)
Indications (158)
Infectious disease (3151)
Inflammatory bowel disease (218)
Inflation Reduction Act (17)
Influenza (131)
Intellectual property (279)
Interviews (346)
IPO (16967)
IRA (53)
Job creations (3739)
Job search strategy (1504)
JPM (67)
Kidney cancer (18)
Labor market (92)
Layoffs (598)
Leadership (36)
Legal (8216)
Liver cancer (100)
Longevity (28)
Lung cancer (734)
Lymphoma (413)
Machine learning (53)
Management (59)
Manufacturing (943)
MASH (184)
Medical device (14082)
Medtech (14159)
Mergers & acquisitions (20478)
Metabolic disorders (1481)
mRNA (202)
Multiple sclerosis (177)
NASH (20)
Neurodegenerative disease (410)
Neuropsychiatric disorders (108)
Neuroscience (3276)
Neurotech (1)
NextGen: Class of 2026 (6845)
Non-profit (4678)
Now hiring (73)
Obesity (713)
Opinion (307)
Ovarian cancer (187)
Pain (234)
Pancreatic cancer (262)
Parkinson's disease (353)
Partnered (34)
Patents (560)
Patient recruitment (607)
Peanut (62)
People (60970)
Pharmaceutical (82)
Pharmacy benefit managers (33)
Phase 1 (22757)
Phase 2 (31941)
Phase 3 (23625)
Pipeline (7207)
Policy (323)
Postmarket research (2636)
Preclinical (9740)
Press Release (67)
Prostate cancer (283)
Psychedelics (58)
Radiopharmaceuticals (325)
Rare diseases (1059)
Real estate (6113)
Recruiting (72)
Regulatory (25711)
Reports (54)
Research institute (2532)
Resumes & cover letters (366)
Rett syndrome (32)
RNA editing (22)
RSV (86)
Schizophrenia (174)
Series A (283)
Series B (212)
Service/supplier (11)
Sickle cell disease (114)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (48)
Startups (3841)
State (2)
Stomach cancer (19)
Supply chain (120)
Tariffs (88)
The Weekly (88)
Vaccines (1112)
Venture capital (106)
Weight loss (463)
Women's health (112)
Worklife (20)
Date
Last 7 days (656)
Last 30 days (2482)
Last 365 days (30855)
2026 (8235)
2025 (31174)
2024 (36412)
2023 (41156)
2022 (52435)
2021 (56943)
2020 (55230)
2019 (47811)
2018 (36021)
2017 (33231)
2016 (32658)
2015 (38705)
2014 (32472)
2013 (27481)
2012 (29567)
2011 (30206)
2010 (28301)
Location
Africa (784)
Alabama (96)
Alaska (7)
Arizona (343)
Arkansas (15)
Asia (41393)
Australia (6883)
California (12514)
Canada (3537)
China (1282)
Colorado (538)
Connecticut (541)
Delaware (369)
Europe (90917)
Florida (1860)
Georgia (400)
Hawaii (3)
Idaho (64)
Illinois (1056)
India (81)
Indiana (564)
Iowa (24)
Japan (495)
Kansas (133)
Kentucky (47)
Louisiana (39)
Maine (73)
Maryland (1513)
Massachusetts (9057)
Michigan (350)
Minnesota (688)
Mississippi (6)
Missouri (140)
Montana (35)
Nebraska (29)
Nevada (135)
New Hampshire (87)
New Jersey (3338)
New Mexico (31)
New York (3293)
North Carolina (1644)
North Dakota (9)
Northern California (6156)
Ohio (371)
Oklahoma (22)
Oregon (45)
Pennsylvania (2513)
Puerto Rico (26)
Rhode Island (51)
South America (1149)
South Carolina (76)
South Dakota (1)
Southern California (4907)
Tennessee (200)
Texas (1959)
United States (44540)
Utah (374)
Vermont (1)
Virginia (301)
Washington D.C. (81)
Washington State (1025)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
748,642 Results for "il therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
J&J Wins FDA Nod for First Targeted Oral Anti-IL-23 Therapy for Plaque Psoriasis
Icotyde, co-developed by Johnson & Johnson and Protagonist Therapeutics, is backed by data from the Phase 3 ICONIC program, which, among other advantages, showed significant superiority over Bristol Myers Squibb’s Sotyktu.
March 18, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
February 24, 2026
·
5 min read
Press Releases
Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting
March 17, 2026
·
4 min read
Collaboration
Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline
CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions.
February 18, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
February 9, 2026
·
5 min read
Press Releases
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
March 2, 2026
·
5 min read
Press Releases
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
December 18, 2025
·
3 min read
Press Releases
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
January 8, 2026
·
8 min read
Press Releases
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
March 18, 2026
·
5 min read
Press Releases
A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster
April 2, 2026
·
2 min read
1 of 74,865
Next
